Refining Vancomycin Protein Binding Estimates: Identification of Clinical Factors That Influence Protein Binding

被引:69
作者
Butterfield, Jill M.
Patel, Nimish
Pai, Manjunath P.
Rosano, Thomas G. [3 ]
Drusano, George L. [2 ]
Lodise, Thomas P. [1 ,2 ]
机构
[1] Albany Coll Pharm & Hlth Sci, Dept Pharm Practice, Albany, NY 12208 USA
[2] Ordway Res Inst, Albany, NY USA
[3] Albany Med Ctr Hosp & Coll, Albany, NY USA
关键词
SERUM BACTERICIDAL ACTIVITIES; STAPHYLOCOCCUS-AUREUS; INTRAVENOUS VANCOMYCIN; RENAL-FAILURE; PHARMACOKINETICS; DRUG; PHARMACODYNAMICS; ULTRAFILTRATION; TEICOPLANIN; INFECTIONS;
D O I
10.1128/AAC.01674-10
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
While current data indicate only free (unbound) drug is pharmacologically active and is most predictive of response, pharmacodynamic studies of vancomycin have been limited to measurement of total concentrations. The protein binding of vancomycin is thought to be approximately 50%, but considerable variability surrounds this estimate. The present study sought to determine the extent of vancomycin protein binding, to identify factors that modulate its binding, and to create and validate a prediction tool to estimate the extent of protein binding based on individual clinical factors. This single-site prospective cohort study included hospitalized adult patients treated with vancomycin and with a vancomycin serum concentration determination available. Linear regression was used to predict the free vancomycin concentration (f[vanco]) and to determine the clinical factors modulating vancomycin protein binding. Among the 50 patients in the study, the mean protein binding was 41.5%. The strongest predictor of f[vanco] was the total vancomycin concentration (total [vanco]), and this was modified by dialysis and total protein of >= 6.7 g/dl as covariates. The algebraic expression from the final prediction model was f[vanco] = 0.643 + 0.560 x total [vanco] - {0.067 x total [vanco] x D} - {0.071 x total [vanco] x TP} where D = 1 if dialysis dependent or 0 if not dialysis dependent, and TP = 1 if total protein is >= 6.7 g/dl or 0 if total protein is <6.7 g/dl. The R-2 of the final prediction model was 0.959 (P < 0.001). Validation of our model was performed in 13 patients, and the predictive performance was highly favorable (R-2 was 0.9, and bias and precision were 0.18 and 0.18, respectively). Prediction models such as ours can be utilized in future pharmacokinetics and pharmacodynamics studies evaluating the exposure-response profile and to determine the pharmacodynamic target of interest as it relates to the free concentration.
引用
收藏
页码:4277 / 4282
页数:6
相关论文
共 35 条
  • [1] VANCOMYCIN SERUM-PROTEIN BINDING DETERMINATION BY ULTRAFILTRATION
    ACKERMAN, BH
    TAYLOR, EH
    OLSEN, KM
    ABDELMALAK, W
    PAPPAS, AA
    [J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1988, 22 (04): : 300 - 303
  • [2] VANCOMYCIN PROTEIN-BINDING IN PATIENTS WITH INFECTIONS CAUSED BY STAPHYLOCOCCUS-AUREUS
    ALBRECHT, LM
    RYBAK, MJ
    WARBASSE, LH
    EDWARDS, DJ
    [J]. DICP-THE ANNALS OF PHARMACOTHERAPY, 1991, 25 (7-8): : 713 - 715
  • [3] COMPARATIVE EFFECT OF PROTEIN-BINDING ON THE KILLING ACTIVITIES OF TEICOPLANIN AND VANCOMYCIN
    BAILEY, EM
    RYBAK, MJ
    KAATZ, GW
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (06) : 1089 - 1092
  • [4] Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections
    Berthoin, Karine
    Ampe, Els
    Tulkens, Paul M.
    Carryn, Stephane
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 34 (06) : 555 - 560
  • [5] Human serum alpha(1) acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease
    Bilello, JA
    Bilello, PA
    Stellrecht, K
    Leonard, J
    Norbeck, DW
    Kempf, DJ
    Robins, T
    Drusano, GL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) : 1491 - 1497
  • [6] PROTEIN-BINDING OF VANCOMYCIN IN A PATIENT WITH IMMUNOGLOBULIN-A MYELOMA
    CANTU, TG
    DICK, JD
    ELLIOTT, DE
    HUMPHREY, RL
    KORNHAUSER, DM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (07) : 1459 - 1461
  • [7] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [8] Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
    Craig, WA
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) : 1 - 10
  • [9] Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid
    Craig, WA
    [J]. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2003, 17 (03) : 479 - +
  • [10] SIGNIFICANCE OF SERUM-PROTEIN AND TISSUE BINDING OF ANTIMICROBIAL AGENTS
    CRAIG, WA
    KUNIN, CM
    [J]. ANNUAL REVIEW OF MEDICINE, 1976, 27 : 287 - 300